Review: Angiotensin-receptor blockers do not reduce mortality or hospitalization rates in heart failure

Kitzman, Dalane W.
September 2002
ACP Journal Club;Sep/Oct2002, Vol. 137 Issue 2, p48
Academic Journal
Discusses the effect of angiotensin-receptor blockers on mortality and hospitalization rates in patients with heart failure. Meta-analysis of randomized controlled trials; Analysis of death and hospitalization outcomes between angiotensin-receptor blockers versus placebo or angiotensin-converting enzyme inhibitors at four weeks to 1.5 years; Information on data sources and study selection.


Related Articles

  • Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: The CHARM Program. Mitchell, Gary F.; Arnold, J. Malcolm O.; Dunlap, Mark E.; O'Brien, Terrence X.; Marchiori, Gordon; Warner, Elaine; Granger, Christopher B.; Desai, Shashank S.; Pfeffer, Marc A. // European Journal of Heart Failure;Mar2006, Vol. 8 Issue 2, p191 

    Abstract: Background: Abnormal large artery function and increased pulsatile load are exacerbated by excess angiotensin-II acting through the AT1 receptor and contribute to the pathogenesis and progression of chronic heart failure (CHF). Aims: To evaluate effects of the AT1 receptor blocker...

  • The CHARM Program: Study Design Leads to Findings of Clinical and Public Health Importance. Hennekens, Charles H.; Pfeffer, Marc A.; Swedherg, Karl // Journal of Cardiovascular Pharmacology & Therapeutics;Jun2007, Vol. 12 Issue 2, p124 

    The article presents information on the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program that was designed to test whether the angiotensin-receptor blocker candesartan would provide significant additive mortality and morbidity benefits to patients...

  • ARBs reduce diabetes in heart failure by up to 40%. Bowden, Rachel // GP: General Practitioner;7/15/2005, p13 

    The article focuses on an international study, which shows that angiotensin receptor blockers (ARBs) could reduce the risk of type-2 diabetes by up to 40 per cent in patients with heart failure. The researchers analyzed data from the candesartan in heart failure, assessment of reduction in...

  • A major trial of an angiotensin-receptor blocker for heart failure.  // Patient Care;2/15/2002, Vol. 36 Issue 3, p8 

    Reports on the outcome of a trial of an angiotensin-receptor blocker for heart failure. Comparison of the combined end point of mortality and morbidity in patients who received valsartan with those who received placebo; Outcome of treatment with valsartan; Safety of combining angiotensin...

  • Angiotensin receptor blockers not equivalent to ACE inhibitors for heart failure. Slawson, James G.; Meurer, Linda N. // Journal of Family Practice;Jun2002, Vol. 51 Issue 6, p508 

    The article examines the effectiveness of angiotensin receptor blockers (ARB) in the treatment of heart failure. Various studies have been identified comparing ARB with placebo or angiotensin-converting enzyme (ACE) inhibitors published before May 2001 through a search of relevant databases....

  • ARB fails to reduce heart failure deaths, trial shows. Tanday, Sanjay // GP: General Practitioner;11/21/2008, p12 

    The article discusses the study regarding the efficacy of angiotensin receptor blocker (ARB) irbesartan. The study conducted by the American Heart Association found that ARB fails to reduce death caused by heart failure (HF). The study was conducted among patients who received 300 milligrams of...

  • Lack of Deleterious Interaction Between Angiotensin Receptor Blockers and �-Blockers in the Treatment of Patients With Heart Failure. Hennekens, Charles H.; Kowalczykowski, Magda; Hollar, Danielle // Journal of Cardiovascular Pharmacology & Therapeutics;Jun2006, Vol. 11 Issue 2, p149 

    Examines the lack of deleterious interaction between angiotensin receptor blockers and ?-blockers in heart failure patients. Overview of the U.S. Food and Drug Administration-approved heart failure indication for candesartan; Trial to test whether candesartan reduced risk of cardiovascular...

  • Effects of Carvedilol in the treatment of heart failure. Huffman, Grace Brooke // American Family Physician;6/1/1997, Vol. 55 Issue 8, p2834 

    Presents a summary of the article `Double-blind, Placebo-controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure. The PRECISE Trial,' by M. Packer, et al from `Circulation' dated 1996. Scope of the study; Findings of the study.

  • Baseline demographics of the Valsartan Heart Failure Trial. Cohn, Jay N.; Tognoni, Gianni; Glazer, Robert; Spormann, Dirk // European Journal of Heart Failure;Dec2000, Vol. 2 Issue 4, p439 

    Background: The Valsartan Heart Failure Trial (Val-HeFT) is the first large-scale randomized, multinational clinical study to assess the efficacy and safety of valsartan, an angiotensin II receptor blocker, added to conventional therapy, including angiotensin-converting enzyme inhibitors, in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics